Results showed that of those patients currently on warfarin surveyed, 86% of patients agreed that they would consider patient self-monitoring to give them a life free from frequent clinic visits as they could quickly and easily send results to their healthcare professional.

With the CoaguChek INRange meter, important reminders can be set up for events such as when to test or when to take medication. Comments can be added to specific results and these can be displayed in graphs, allowing patients to see how many of their results fall within their target therapeutic range.

Trudie Lobban MBE, founder and CEO of the Atrial Fibrillation Association, said: “The AF Association welcomes the launch of the INRange meter that can be a sustainable solution to the needs of patients on warfarin. Of patients surveyed who currently do not self-monitor, 86% said that they would consider doing so.”

Several previous trials have demonstrated that for those on long term warfarin, patient self-monitoring significantly improves time in therapeutic range (TTR) and leads to better outcomes including 50% reduction in thromboembolism and 13% reduction in major haemorrhage.